Globus Medical, Inc. (GMED)

Market Cap	7.77B
Revenue (ttm)	2.51B
Net Income (ttm)	185.56M
Shares Out	135.38M
EPS (ttm)	1.34
PE Ratio	42.95
Forward PE	17.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,338,912
Open	57.08
Previous Close	57.12
Day's Range	57.05 - 58.14
52-Week Range	54.48 - 94.93
Beta	1.20
Analysts	Buy
Price Target	94.30 (+64.37%)
Earnings Date	Aug 5, 2025

About GMED

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Aug 3, 2012
• Employees: 5,300
• Stock Exchange: NYSE
• Ticker Symbol: GMED
• Website: https://www.globusmedical.com

Financial Performance

In 2024, Globus Medical's revenue was $2.52 billion, an increase of 60.62% compared to the previous year's $1.57 billion. Earnings were $102.98 million, a decrease of -16.19%.

Analyst Summary

According to 13 analysts, the average rating for GMED stock is "Buy." The 12-month stock price target is $94.3, which is an increase of 64.37% from the latest price.

Price Target

$94.3

(64.37% upside)

Analyst Consensus: Buy